News and Announcements
Shivom Strikes Strategic Alliance with Genetic Technologies Limited (ASX: GTG)
- Published March 20, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Genetic Technologies Limited a diversified molecular diagnostics company; provider of BREVAGenplus: registered, a first-in-class, clinically validated risk assessment test for sporadic breast cancer, has announced its plans to collaborate with Project Shivom.
The partnership aims to build on the technologies of GTG Labs and Project Shivom’s reach. Dr Paul Kasian, Genetic Technologies’ Chairman commented: “The Board is excited about the opportunity to collaborate with Project Shivom on its unique blockchain platform. Where the formal terms are agreed with Project Shivom, access to such a large database of genomic data would allow GTG to utilize its SNP based risk assessment technologies.”
To read the full ASX announcement made by GTG please click here.
About Shivom
Shivom combines blockchain, A.I., DNA sequencing & cryptography to enable secure and personalized medicine. The Shivom platform works on collaboration & integrity, allowing people to own, manage and monetize their data. By creating a web-marketplace, a network of genomic counsellors, and a not-for-profit drug research unit, Shivom will build a global healthcare ecosystem, reaching even low-income countries.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
